Symptom Prevalence in Spanish and Colombian Oncology Patients Measured with the MSAS
Cancer patients experience several symptoms throughout their illness and the treatments they receive. While this pathology represents a worldwide health problem, knowing the symptom prevalence in oncology patients remains a challenge; validated tools to obtain this information are essential. Further...
Gespeichert in:
| Veröffentlicht in: | Cancers 2022-03, Vol.14 (7), p.1624 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 7 |
| container_start_page | 1624 |
| container_title | Cancers |
| container_volume | 14 |
| creator | Llamas-Ramos, Inés Llamas-Ramos, Rocío Carrillo-González, Gloria Mabel Sepúlveda-Ramírez, Jennifer Vargas-Rosero, Elizabeth |
| description | Cancer patients experience several symptoms throughout their illness and the treatments they receive. While this pathology represents a worldwide health problem, knowing the symptom prevalence in oncology patients remains a challenge; validated tools to obtain this information are essential. Furthermore, this prevalence information would help health professionals to establish appropriate treatments. The objective of this study was to ascertain the symptom prevalence in cancer patients from Spain and Colombia to improve future approaches. The frequency, severity, and distress of 32 symptoms from a validated scale experienced by cancer patients from Spain and Colombia were measured. Two hundred and forty-six patients (49.7%) who attended the Day University Hospital of Salamanca (Spain) and two hundred and forty-nine outpatients (50.3%) of the San Diego Cancer Center (Colombia) between 2016 and 2019 participated in the study. All patients filled in the Assessment Scale only once. Four hundred and ninety-five patients (333 women (67.3%) and 162 men (32.7%)) completed the Memorial Symptom Assessment Scale (Spanish version). The most frequent symptom for both samples (Spanish and Colombian) was "lack of energy" (38.4% and 13.7%, respectively). The most severe symptoms for the Spanish and Colombian samples were "problems with sexual interest or activity" (38.4%) and "dry mouth" (13.7%), respectively, and both samples agreed on the most distressing symptom: "hair loss" (Spanish, 38%; Colombian, 10.1%). The Spanish version of the MSAS has proven to be a valid and reliable tool in Spanish-speaking countries to obtain the most prevalent, severe, and distressing symptoms in Spanish and Colombian oncology patients. The prevalence of symptoms was demonstrated to be similar across both countries, and the results will help to design and adapt treatments for cancer patients, targeting these symptoms to reduce or avoid them and thus improving their quality of life. |
| doi_str_mv | 10.3390/cancers14071624 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8996859</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2648982069</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-41127fca830509f94916f5ddea9fa927f48a45e9798f0cf07cfc394dfff94883</originalsourceid><addsrcrecordid>eNpdkc1LAzEQxYMoWtSzNwl48VKbbLLZ5CJI8QtaWmjvIWYTG9lNarKr9L83pVXUuczA_ObxhgfABUY3hAg00sprExOmqMKsoAdgUKCqGDIm6OGv-QScp_SGchGCK1YdgxNSUsSIYAOwXGzadRdaOI_mQzUmK0Ln4WKtvEsrqHwNx6EJ7YtTHs68zvPrBs5V54zvEpwalfpoavjpuhXsVgZOF3eLM3BkVZPM-b6fguXD_XL8NJzMHp_Hd5OhpgXuhhTjorJacYJKJKygAjNb1rVRwiqRV5QrWhpRCW6RtqjSVhNBa2szyzk5Bbc72XX_0ppaZ0dRNXIdXaviRgbl5N-Ndyv5Gj4kF4LxUmSB671ADO-9SZ1sXdKmaZQ3oU-yYFSU2QgqMnr1D30LffT5uy3FBS8Q2wqOdpSOIaVo7I8ZjOQ2M_kvs3xx-fuHH_47IfIFT3GUCw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2648982069</pqid></control><display><type>article</type><title>Symptom Prevalence in Spanish and Colombian Oncology Patients Measured with the MSAS</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Llamas-Ramos, Inés ; Llamas-Ramos, Rocío ; Carrillo-González, Gloria Mabel ; Sepúlveda-Ramírez, Jennifer ; Vargas-Rosero, Elizabeth</creator><creatorcontrib>Llamas-Ramos, Inés ; Llamas-Ramos, Rocío ; Carrillo-González, Gloria Mabel ; Sepúlveda-Ramírez, Jennifer ; Vargas-Rosero, Elizabeth</creatorcontrib><description>Cancer patients experience several symptoms throughout their illness and the treatments they receive. While this pathology represents a worldwide health problem, knowing the symptom prevalence in oncology patients remains a challenge; validated tools to obtain this information are essential. Furthermore, this prevalence information would help health professionals to establish appropriate treatments. The objective of this study was to ascertain the symptom prevalence in cancer patients from Spain and Colombia to improve future approaches. The frequency, severity, and distress of 32 symptoms from a validated scale experienced by cancer patients from Spain and Colombia were measured. Two hundred and forty-six patients (49.7%) who attended the Day University Hospital of Salamanca (Spain) and two hundred and forty-nine outpatients (50.3%) of the San Diego Cancer Center (Colombia) between 2016 and 2019 participated in the study. All patients filled in the Assessment Scale only once. Four hundred and ninety-five patients (333 women (67.3%) and 162 men (32.7%)) completed the Memorial Symptom Assessment Scale (Spanish version). The most frequent symptom for both samples (Spanish and Colombian) was "lack of energy" (38.4% and 13.7%, respectively). The most severe symptoms for the Spanish and Colombian samples were "problems with sexual interest or activity" (38.4%) and "dry mouth" (13.7%), respectively, and both samples agreed on the most distressing symptom: "hair loss" (Spanish, 38%; Colombian, 10.1%). The Spanish version of the MSAS has proven to be a valid and reliable tool in Spanish-speaking countries to obtain the most prevalent, severe, and distressing symptoms in Spanish and Colombian oncology patients. The prevalence of symptoms was demonstrated to be similar across both countries, and the results will help to design and adapt treatments for cancer patients, targeting these symptoms to reduce or avoid them and thus improving their quality of life.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers14071624</identifier><identifier>PMID: 35406396</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Cancer ; Cancer therapies ; Chemotherapy ; Cognitive ability ; Disease ; Hospitals ; Hypotheses ; Informed consent ; Life expectancy ; Medical personnel ; Mortality ; Oncology ; Patients ; Prostate ; Quality of life ; Questionnaires ; Tumors ; Womens health</subject><ispartof>Cancers, 2022-03, Vol.14 (7), p.1624</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-41127fca830509f94916f5ddea9fa927f48a45e9798f0cf07cfc394dfff94883</citedby><cites>FETCH-LOGICAL-c421t-41127fca830509f94916f5ddea9fa927f48a45e9798f0cf07cfc394dfff94883</cites><orcidid>0000-0002-5606-261X ; 0000-0003-2710-4320 ; 0000-0003-0311-898X ; 0000-0003-4513-104X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996859/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996859/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35406396$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Llamas-Ramos, Inés</creatorcontrib><creatorcontrib>Llamas-Ramos, Rocío</creatorcontrib><creatorcontrib>Carrillo-González, Gloria Mabel</creatorcontrib><creatorcontrib>Sepúlveda-Ramírez, Jennifer</creatorcontrib><creatorcontrib>Vargas-Rosero, Elizabeth</creatorcontrib><title>Symptom Prevalence in Spanish and Colombian Oncology Patients Measured with the MSAS</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Cancer patients experience several symptoms throughout their illness and the treatments they receive. While this pathology represents a worldwide health problem, knowing the symptom prevalence in oncology patients remains a challenge; validated tools to obtain this information are essential. Furthermore, this prevalence information would help health professionals to establish appropriate treatments. The objective of this study was to ascertain the symptom prevalence in cancer patients from Spain and Colombia to improve future approaches. The frequency, severity, and distress of 32 symptoms from a validated scale experienced by cancer patients from Spain and Colombia were measured. Two hundred and forty-six patients (49.7%) who attended the Day University Hospital of Salamanca (Spain) and two hundred and forty-nine outpatients (50.3%) of the San Diego Cancer Center (Colombia) between 2016 and 2019 participated in the study. All patients filled in the Assessment Scale only once. Four hundred and ninety-five patients (333 women (67.3%) and 162 men (32.7%)) completed the Memorial Symptom Assessment Scale (Spanish version). The most frequent symptom for both samples (Spanish and Colombian) was "lack of energy" (38.4% and 13.7%, respectively). The most severe symptoms for the Spanish and Colombian samples were "problems with sexual interest or activity" (38.4%) and "dry mouth" (13.7%), respectively, and both samples agreed on the most distressing symptom: "hair loss" (Spanish, 38%; Colombian, 10.1%). The Spanish version of the MSAS has proven to be a valid and reliable tool in Spanish-speaking countries to obtain the most prevalent, severe, and distressing symptoms in Spanish and Colombian oncology patients. The prevalence of symptoms was demonstrated to be similar across both countries, and the results will help to design and adapt treatments for cancer patients, targeting these symptoms to reduce or avoid them and thus improving their quality of life.</description><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Cognitive ability</subject><subject>Disease</subject><subject>Hospitals</subject><subject>Hypotheses</subject><subject>Informed consent</subject><subject>Life expectancy</subject><subject>Medical personnel</subject><subject>Mortality</subject><subject>Oncology</subject><subject>Patients</subject><subject>Prostate</subject><subject>Quality of life</subject><subject>Questionnaires</subject><subject>Tumors</subject><subject>Womens health</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkc1LAzEQxYMoWtSzNwl48VKbbLLZ5CJI8QtaWmjvIWYTG9lNarKr9L83pVXUuczA_ObxhgfABUY3hAg00sprExOmqMKsoAdgUKCqGDIm6OGv-QScp_SGchGCK1YdgxNSUsSIYAOwXGzadRdaOI_mQzUmK0Ln4WKtvEsrqHwNx6EJ7YtTHs68zvPrBs5V54zvEpwalfpoavjpuhXsVgZOF3eLM3BkVZPM-b6fguXD_XL8NJzMHp_Hd5OhpgXuhhTjorJacYJKJKygAjNb1rVRwiqRV5QrWhpRCW6RtqjSVhNBa2szyzk5Bbc72XX_0ppaZ0dRNXIdXaviRgbl5N-Ndyv5Gj4kF4LxUmSB671ADO-9SZ1sXdKmaZQ3oU-yYFSU2QgqMnr1D30LffT5uy3FBS8Q2wqOdpSOIaVo7I8ZjOQ2M_kvs3xx-fuHH_47IfIFT3GUCw</recordid><startdate>20220323</startdate><enddate>20220323</enddate><creator>Llamas-Ramos, Inés</creator><creator>Llamas-Ramos, Rocío</creator><creator>Carrillo-González, Gloria Mabel</creator><creator>Sepúlveda-Ramírez, Jennifer</creator><creator>Vargas-Rosero, Elizabeth</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5606-261X</orcidid><orcidid>https://orcid.org/0000-0003-2710-4320</orcidid><orcidid>https://orcid.org/0000-0003-0311-898X</orcidid><orcidid>https://orcid.org/0000-0003-4513-104X</orcidid></search><sort><creationdate>20220323</creationdate><title>Symptom Prevalence in Spanish and Colombian Oncology Patients Measured with the MSAS</title><author>Llamas-Ramos, Inés ; Llamas-Ramos, Rocío ; Carrillo-González, Gloria Mabel ; Sepúlveda-Ramírez, Jennifer ; Vargas-Rosero, Elizabeth</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-41127fca830509f94916f5ddea9fa927f48a45e9798f0cf07cfc394dfff94883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Cognitive ability</topic><topic>Disease</topic><topic>Hospitals</topic><topic>Hypotheses</topic><topic>Informed consent</topic><topic>Life expectancy</topic><topic>Medical personnel</topic><topic>Mortality</topic><topic>Oncology</topic><topic>Patients</topic><topic>Prostate</topic><topic>Quality of life</topic><topic>Questionnaires</topic><topic>Tumors</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Llamas-Ramos, Inés</creatorcontrib><creatorcontrib>Llamas-Ramos, Rocío</creatorcontrib><creatorcontrib>Carrillo-González, Gloria Mabel</creatorcontrib><creatorcontrib>Sepúlveda-Ramírez, Jennifer</creatorcontrib><creatorcontrib>Vargas-Rosero, Elizabeth</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Llamas-Ramos, Inés</au><au>Llamas-Ramos, Rocío</au><au>Carrillo-González, Gloria Mabel</au><au>Sepúlveda-Ramírez, Jennifer</au><au>Vargas-Rosero, Elizabeth</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Symptom Prevalence in Spanish and Colombian Oncology Patients Measured with the MSAS</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2022-03-23</date><risdate>2022</risdate><volume>14</volume><issue>7</issue><spage>1624</spage><pages>1624-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Cancer patients experience several symptoms throughout their illness and the treatments they receive. While this pathology represents a worldwide health problem, knowing the symptom prevalence in oncology patients remains a challenge; validated tools to obtain this information are essential. Furthermore, this prevalence information would help health professionals to establish appropriate treatments. The objective of this study was to ascertain the symptom prevalence in cancer patients from Spain and Colombia to improve future approaches. The frequency, severity, and distress of 32 symptoms from a validated scale experienced by cancer patients from Spain and Colombia were measured. Two hundred and forty-six patients (49.7%) who attended the Day University Hospital of Salamanca (Spain) and two hundred and forty-nine outpatients (50.3%) of the San Diego Cancer Center (Colombia) between 2016 and 2019 participated in the study. All patients filled in the Assessment Scale only once. Four hundred and ninety-five patients (333 women (67.3%) and 162 men (32.7%)) completed the Memorial Symptom Assessment Scale (Spanish version). The most frequent symptom for both samples (Spanish and Colombian) was "lack of energy" (38.4% and 13.7%, respectively). The most severe symptoms for the Spanish and Colombian samples were "problems with sexual interest or activity" (38.4%) and "dry mouth" (13.7%), respectively, and both samples agreed on the most distressing symptom: "hair loss" (Spanish, 38%; Colombian, 10.1%). The Spanish version of the MSAS has proven to be a valid and reliable tool in Spanish-speaking countries to obtain the most prevalent, severe, and distressing symptoms in Spanish and Colombian oncology patients. The prevalence of symptoms was demonstrated to be similar across both countries, and the results will help to design and adapt treatments for cancer patients, targeting these symptoms to reduce or avoid them and thus improving their quality of life.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35406396</pmid><doi>10.3390/cancers14071624</doi><orcidid>https://orcid.org/0000-0002-5606-261X</orcidid><orcidid>https://orcid.org/0000-0003-2710-4320</orcidid><orcidid>https://orcid.org/0000-0003-0311-898X</orcidid><orcidid>https://orcid.org/0000-0003-4513-104X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2022-03, Vol.14 (7), p.1624 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8996859 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Cancer Cancer therapies Chemotherapy Cognitive ability Disease Hospitals Hypotheses Informed consent Life expectancy Medical personnel Mortality Oncology Patients Prostate Quality of life Questionnaires Tumors Womens health |
| title | Symptom Prevalence in Spanish and Colombian Oncology Patients Measured with the MSAS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T13%3A23%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Symptom%20Prevalence%20in%20Spanish%20and%20Colombian%20Oncology%20Patients%20Measured%20with%20the%20MSAS&rft.jtitle=Cancers&rft.au=Llamas-Ramos,%20In%C3%A9s&rft.date=2022-03-23&rft.volume=14&rft.issue=7&rft.spage=1624&rft.pages=1624-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers14071624&rft_dat=%3Cproquest_pubme%3E2648982069%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2648982069&rft_id=info:pmid/35406396&rfr_iscdi=true |